FlyingEagle (@FlyingEagle86) header
FlyingEagle (@FlyingEagle86) profile picture

Not a financial advisor.

Joined August 2020
Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)Photo by FlyingEagle (@FlyingEagle86)
$capr I cannot share this impactful video enough. Currently listening to Linda speak today just reassures how powerful Deramiocel is for these young boys. Keep sharing with the world as the OP says so their voices are heard.
2
2
8
1,497
FlyingEagle retweeted
$CAPR 28 investigators who ran HOPE-3, with more deramiocel experience than any physicians anywhere, say it slows upper limb loss. They also wrote that a new 12–18 month placebo trial in advanced DMD would be unethical. That's a strong statement from clinicians, not the company.
3
20
1,137
2/2 In September, the FDA approved the therapy, which ARM member Ultragenyx brought from clinical trials to approval. Eliza’s story shows what CGTs can mean for families facing diseases that once had no treatment options.
1
1
156
👇🏽SHARE this OpEd by @Elijahjstacy. Both Elijah and his brother are battling #Duchenne. They need the FDA to arm them in that fight. On a bipartisan basis, Congress has repeatedly called out the @FDA for not honoring Congessional intent in 21st Century Cures. @FDADrugs and @FDA_KyleD Congess and @POTUS have spoken. Now the FDA now has its 1st chance to show whether it will honor its own proposed Rare Disease Framework by approving @Capricor's #deramiocel. #RareDiseases #PDUFA #patientadvocacy #healthcare #MedTwitter #MedX #Neurology #neuromuscular #MuscularDystrophy @GOPHELP @HELPCmteDems @EnergyCommerce @HouseCommerce @AnnieAndrewsMD @AbdulElSayed @DrAmishShah @DrPanMD @HamawyForNJ @RepKimSchrier @RepHerbConaway @herbconaway @RepDexterOR @DoctorMaxine @KellyMorrisonMN @Morrison4MN @RepRaulRuizMD @Bilirakis @DorisMatsui @RepGuthrie @RepAndyHarrisMD @RepJohnJoyce @RepMGriffith @DrRandPaul @SenJohnBarrasso @SenSanders @lisamurkowski @SenatorWicker @SenGillibrand
8
1
22
1,756
FlyingEagle retweeted
@FDADrugs @RobertKennedyJr @Capricor The Science, the Patients, the DMD community, the Lancet, the American Pediatric Heart Association, the Principal Investigators for Hope 2 and Hope 3 are all aligned how is this even a question that the FDA wouldn’t approve Deramiocel?!
2
1
18
457
FlyingEagle retweeted
Please take a minute to read what Dr. Cassidy, DMD patient & patient representative for Capricor’s Adcom, wrote about the upcoming FDA decision on deramiocel. I believe his opinion on the matter carries significant weight considering he went back and forth with regulators, not just recently, but many times in the past regarding other drugs for DMD. The DMD is loudly calling for the approval of deramiocel. We HOPE to see it approved soon, @FDA @FDADrugs @FDA_KyleD!
14
22
4
117
7,276
Asking @FDA_KyleD and @FDAdrugs to hear their pleas. Grant accelerated approval of @Capricor's #deramiocel. Give him a chance. #TimeEqualsMuscle #EndDMD #EndDuchenne #Duchenne
Washington, D.C., may be buzzing today about the latest political fight and the withdrawal of Dr. Overton’s nomination. But 2,000 miles away, life in our home goes on. And so does Duchenne. The disease doesn't pause for political drama. It doesn't wait for a new @FDA commissioner. Every day, it keeps attacking my son's muscles. And every day, we have to keep fighting to preserve them.
2
11
406
The FDA Commissioner role is open again. Dr. Heidi Overton’s nomination was pulled the night before her Senate committee vote. Whatever the internal reasons, this creates a rare opening to get the leadership right for American patients and for the innovation that actually reaches them. Here’s what the next Commissioner needs to be. Not a wish list. A baseline: You cannot regulate what you have never lived. The person in this seat should have spent real time on the other side of the table—building a product in biotech, pharma, or devices—and felt the weight of regulatory decisions as the recipient (sometimes the victim). That experience is not optional. Career government officials and pure academics can be talented, but they have never had a program delayed, a trial redesigned, or a company nearly killed by a decision whose full consequences they never had to carry. The ethics rules make it extremely difficult for anyone with industry experience to take this job because of the divestiture requirements. The result is that the role often defaults to people who have never created anything. That may be administratively easier. There is a price. This person must be a licensed physician—ideally a physician-scientist—who has done both basic and clinical research and who has actually taken care of patients. An active license is ideal. They need to understand, firsthand, what patients face, including patients with rare diseases. For many of those conditions it is mathematically nearly impossible to hit a p-value of 0.05, the arbitrary threshold we treat as the definition of statistical significance. That reality has to be lived, not just read about. The role is sacred. It involves life-and-death decisions for millions of people. It is therefore not a platform for partisan ideology. Americans are sick of extreme partisanship. The next Commissioner should be objective, serve all Americans, and recognize that this job is not subject to partisan manipulation. They should be blindly loyal to exactly one large and powerful special-interest group: THE AMERICAN PEOPLE. Full stop. They should be well-spoken and confident in public settings, yet humble enough to welcome feedback and constructive criticism. They should not arrive with their mind made up on specific drugs or classes of drugs before they have seen the data. The FDA’s job is not to decide whether a particular patient should receive a particular drug. That decision belongs to the physician and the patient once the science is sound and the information is clear. Every regulatory choice carries 2 risks: the risk of approving something that later proves harmful, and the risk of not approving something that could have helped. Both are real. For patients with serious or rare conditions and few options, the second risk is often larger. This is also a national-security position. It requires a counterintelligence background check (don’t ask how I know 😉) for a reason: the wrong decision or the wrong public (or private) statement can do real harm. The person who holds it should treat that responsibility with the seriousness it deserves—focused on the work, not on being a constant public figure, & never hinting at confidential information. They may hold strong personal, cultural, or religious beliefs. Those beliefs stay at the door. The job is to follow the law and to do what is medically, scientifically, and ethically right for American patients. Bring back open, FAIR advisory committee meetings so the public can see how decisions are made. Keep asking not only “Is it safe enough to approve?” but “What happens if we do not?” Protect the public from products that offer real risk with no benefit, while trusting informed patients and physicians when credible evidence exists that a treatment can help This is a moment to choose leadership that is responsive to the needs of all Americans—objective, compassionate, and thoughtful. American patients & American innovation are counting on it.
32
51
16
172
20,032
FlyingEagle retweeted
.@POTUS give @houmanhemmati a call to be the next FDA commissioner. Incredibly qualified, scientifically rigorous, and a heart for patients. I am confident that he can restore the American people’s faith in the agency, and win the support of both political persuasions.
11
14
1
91
3,477
Elijah Stacey echos how my 33 year old son with Duchenne feels. My son doesn't have time for the Democrats and The President to make a deal! Everyone diagnosed with Duchenne deserves options!
5
48
788
$capr Deramiocel shows a recurring favorable upper limb signal across randomized-trial analyses, targeted pooled sensitivities, and delayed-start follow-up. The estimated benefit could preserve meaningful function in a population with substantial unmet need.
1
1
22
872
That supports serious consideration of approval
2
5
121
$capr when it’s all said and done, @FDA has a defensible route to approval and the dmd community has literally zero options and zero time to lose #approvederamiocel
2
2
24
734
FlyingEagle retweeted
I was there in person to hear these testimonies, and it was one of the most powerful FDA Advisory Committee meetings I’ve ever attended. Listening to the patient experience is an important part of the FDA review process. I was grateful to see how closely the committee listened and how much attention they gave to each person who shared their experience. If you missed the meeting or want to hear those voices again, take a few minutes to watch the video compilation shared by @Elijahjstacy, a young man who lives with Duchenne himself. We’re now ten days away from the November 22nd PDUFA date for deramiocel. I’m looking forward to hearing the FDA’s decision and hope it reflects the full body of scientific evidence and the experiences patients and families shared that day. #timeismuscle #duchenne @POTUS @SecKennedy @FDA @FDADrugs @FDA_KyleD
Beyond the statistically significant results in upper-limb function from Capricor’s Phase 3 HOPE-3 trial, published in the prestigious medical journal The Lancet, patient testimony like this brings the clinical data to life, putting the numbers into a deeply personal and human context. This powerful testimony further reinforces why I believe the FDA should approve deramiocel, giving my peers and patients like myself access to a potentially life-changing treatment. $CAPR
1
9
44
1,126
Compelling @Biospace OpEd from @Elijahjstacy and why he's fighting for approval of deramiocel, @Capricor's cell therapy: "Losing the ability to walk isn’t the end of the disease. It’s the start of a new fight to keep the use of your arms and hands." #Deramiocel helps boys and men fight #Duchenne. Trial data showed a clinically meaningful slowing of the loss of upper limb function. @FDA_KyleD @FDADrugs Karim Mikhail please apply the principles of the proposed Rare Disease Framework. Grant accelerated approval of deramiocel. #EndDMD #EndDuchenne #MuscularDystrophy #rarediseases
4
11
293
FlyingEagle retweeted
My friend @Elijahjstacy does such a good job showing how slowing disease progression changes lives, especially for those who have already lost the ability to walk. This is not just a theoretical or academic debate. Real patients are waiting for a chance to slow the relentless progression of DMD. One of those patients is my son. We have to make sure the @FDA is building their guidelines to serve our boys now, not some impossible standard just to prove who’s “right” or “wrong.” Read this piece. @aVoice4ALS @rachelreising96 @Christina4HD @chrispiaOTM29 @destroydisease @laurencurehd @houmanhemmati
3
9
1
48
1,363
FlyingEagle retweeted
The FDA needs to approve deramiocel .. the clinical studies and the voices of those suffering from DMD makes it overwhelming clear that it works @FDADrugs
Beyond the statistically significant results in upper-limb function from Capricor’s Phase 3 HOPE-3 trial, published in the prestigious medical journal The Lancet, patient testimony like this brings the clinical data to life, putting the numbers into a deeply personal and human context. This powerful testimony further reinforces why I believe the FDA should approve deramiocel, giving my peers and patients like myself access to a potentially life-changing treatment. $CAPR
1
6
38
1,125
WOW! The @American_Heart Assn just gave its Outstanding Research Award in Pediatric Cardiology to the lead cardiologist for his work presenting #deramiocel data for boys and men battling #Duchenne. @FDA_KyleD @FDADrugs, the law requires @FDA to conisider expert opinions in evaluating if "substantial evidence" of efficacy exists. If the AHA colleagues are impressed, certainly the @FDA should be too. Apply the principles of the proposed Rare Disease Framework. Grant accelerated approval of deramiocel as the data are reasonably likely to predict a clinically meaningful benefit. #EndDMD #EndDuchenne #MuscularDystrophy #rarediseases #pediatrics #Cardiology #cardiologist
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible. Read the press release: bit.ly/4BMIYM5 #AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
1
5
28
753